

# Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization

José M Ruiz-Moreno<sup>1,2</sup>, Javier A Montero<sup>2,3</sup>, Pedro Amat<sup>2</sup>, Francisco Lugo<sup>2</sup>

<sup>1</sup>Department of Ophthalmology, Albacete Medical School, University of Castilla La Mancha, Spain

<sup>2</sup>Alicante Institute of Ophthalmology, Vitreo-Retinal Unit. Spain

<sup>3</sup>Pro del Río Hortega University Hospital, Ophthalmology Unit, Valladolid, Spain.

**Correspondence to:** Javier A Montero. Pro del Río Hortega University Hospital, Ophthalmology Unit. C/Carraca s/n, Valladolid, 47012, Spain. javmonmor@hotmail.com

Received:2010-04-28 Accepted:2010-05-23

## Abstract

• **AIM:** To report the appearance of choriocapillaris atrophy after combined high dose intravitreal triamcinolone acetonide (TA) and photodynamic therapy (PDT) to treat choroidal neovascularization (CNV) associated with age related macular degeneration (AMD).

• **METHODS:** The present study was retrospective about non-randomized interventional case series. Fifty-one consecutive eyes with subfoveal (all types) CNV associated with AMD were treated by PDT and intravitreal (19.4±2.1)mg per 0.1mL TA at the Alicante Institute of Ophthalmology. The appearance of macular choriocapillaris and retinal pigment epithelium (RPE) atrophy was considered at two years follow-up. Thirty consecutive eyes treated by PDT alone, matched for age, sex, and type and size of CNV were considered as control group.

• **RESULTS:** Twenty-one of 47 eyes in the study group (45%) and 7 of 30 eyes in the control group (23%) developed macular RPE and choriocapillaris atrophy in the treated area at month 24 ( $P=0.04$ , Chi-square test). The greatest diameter of the atrophic areas averaged (5044±1666) $\mu$ m in the study group  $\nu$ s (4345±1550) $\mu$ m in the control group. Mean final best corrected visual acuity (logarithm of minimal angle of resolution) was (0.87±0.33) in the cases with RPE atrophy  $\nu$ s (0.66±0.26) in the cases with no RPE atrophy in the study group ( $P=0.11$ , Mann-Whitney  $U$  test).

• **CONCLUSION:** The association of high doses of intravitreal TA and PDT may increase the risk for RPE and choriocapillaris atrophy.

• **KEYWORDS:** age related macular degeneration; choriocapillaris atrophy; intravitreal triamcinolone; photodynamic therapy; retinal pigment epithelium atrophy

DOI:10.3980/j.issn.2222-3959.2010.02.16

Ruiz-Moreno JM, Montero JA, Amat P, Lugo F. Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization. *Int J Ophthalmol* 2010;3(2):161-163

## INTRODUCTION

Triamcinolone acetonide (TA) is used at variable concentrations to treat macular edema associated with diabetic retinopathy<sup>[1]</sup>, surgery<sup>[2]</sup> and inflammation<sup>[3]</sup>. Due to its antiangiogenic properties it has also been used to treat choroidal neovascularization (CNV) as a unique therapy<sup>[4]</sup> or associated with photodynamic therapy (PDT)<sup>[5,6]</sup>.

Among the side effects of the intravitreal injection of TA, cataracts, high intraocular pressure and sterile and infectious endophthalmitis had been described<sup>[5,7,8]</sup>. Prolonged choroidal hypofluorescence following combined treatment with intravitreal TA and PDT has also been reported<sup>[9]</sup>.

The aim of this study is to describe the appearance of macular choriocapillaris hypofluorescence and RPE atrophy after high dose combined intravitreal TA and PDT to treat CNV associated with age related macular degeneration (AMD) in a consecutive series of patients after two years.

## MATERIALS AND METHODS

**Patients** We have performed a retrospective review of 51 eyes from 51 consecutive patients treated with combined intravitreal TA injections at high doses performed in association with PDT to treat subfoveal (all types) CNV secondary to AMD, at the Alicante Institute of Ophthalmology. TA was injected five days after PDT as previously described. The concentration of injected TA averaged (19.4±2.1)mg per 0.1mL<sup>[7,10]</sup>. We have considered as a control group 30 consecutive patients with AMD-associated subfoveal CNV who were treated at our clinic with standard PDT. Age, sex, best corrected visual acuity (BCVA), CNV size, and lesion type did not show significant differences between both groups at baseline. Written informed consent was obtained after the nature of the procedure had been fully explained to the patients. The procedures were in accordance with the Helsinki Declaration of 1975, as revised in 1983. Data gathering was performed after obtaining written informed consent and approval of the Ethics Committee. Mean age at the end of follow-up was

## RPE atrophy after triamcinolone and PDT

75.2±6.9 (58-86) years, and the male to female ratio was 15/36. Mean age for the control group was 73.9±11.3 (56 to 90) years, and male to female ratio was 12/18. Forty-nine of 51 patients (96%) completed one year follow-up and 47 patients completed the second year follow-up (92%) in the study group.

**Methods** All patients were examined the day after the injection, at day 15, at day 30 and every three months thereafter. Fluorescein angiography (FA) and color retinographies were performed every three months (Imagenet 2000 2.53, Topcon Europe BV, the Netherlands). PDT was performed at three month intervals whenever CNV activity was demonstrated by fluorescein leakage. Intravitreal TA injections were performed in association with PDT at six months intervals if CNV showed activity.


The appearance of atrophic areas of retinal pigment epithelium (RPE) or choriocapillaris hypofluorescence was retrospectively analyzed at 24 months on FA and red free fundus photography by masked observers. One single intravitreal injection of TA was performed in 42 cases and two injections in nine cases. The number of PDT sessions averaged 1.6 during the two year follow-up vs 3.8 for the control group.

## RESULTS


Twenty-one of 47 cases completing two year follow-up (45%) presented macular RPE atrophy and choriocapillaris hypofluorescence in the area treated by PDT as determined by red-free fundus photography, FA and optical coherence tomography (Figure 1) vs seven cases (23%) of the control group ( $P=0.04$ , Chi-square test)(Figure 2). The greatest diameter of the atrophic areas averaged 5044±1666(2454-7303) μm in the study group. Average greatest diameter of the atrophic areas was 4345±1550(3075 to 6825)μm in the control group. Mean final best corrected visual acuity (BCVA) (logarithm of minimal angle of resolution [LogMar]) in the cases with RPE atrophy was (0.87±0.33) vs (0.66±0.26) in cases with no RPE atrophy ( $P=0.11$ , Mann-Whitney  $U$  test). No cases of extramacular RPE atrophy or choriocapillaris hypofluorescence were found.

## DISCUSSION

The rationale for the use of high doses intravitreal TA injection has been to achieve a longer duration of action of the drug in the vitreous cavity. Ranson *et al*<sup>[11]</sup> and Danis *et al*<sup>[12]</sup> have demonstrated the relative safety of intravitreal TA injection to treat CNV associated with AMD. Luttrull *et al*<sup>[9]</sup> have described prolonged choroidal hypoperfusion (PCH) in 37 from 53 eyes (70%) receiving PDT plus intravitreal TA compared to 3 from 27 eyes (11%) in the control group treated only by PDT. PCH was graded in relation to hypoperfusion demonstrated one week after PDT. The authors attributed the increased incidence of PCH in eyes treated with combined therapy to the addition of



**Figure 1** A: Late phase fluorescein angiography (FA) showing subfoveal choroidal neovascularization (CNV) before treatment with best corrected visual acuity (BCVA) 20/400; B: Late phase FA of the same patient as Figure 2A two years after one combined treatment PDT and TA shows marked RPE and choriocapillaris atrophy. BCVA was 20/250; C: Late phase FA showing subfoveal CNV before treatment with BCVA 20/125; D: Late phase FA two years after one combined treatment PDT and TA shows RPE and choriocapillaris atrophy. BCVA was 20/100; E: Optical coherence tomography (vertical scan) of the same patient as Figure 2C and 2D shows a sharp increase of subretinal signal corresponding to RPE atrophy (arrow)



**Figure 2** A: Late phase FA showing subfoveal CNV before treatment with BCVA 20/400; B: Late phase FA two years after four PDT sessions shows marked RPE and choriocapillaris atrophy. BCVA was 20/100; C: Late phase FA showing subfoveal CNV before treatment, BCVA 20/200; D: Late phase FA two years after two PDT sessions shows RPE and choriocapillaris atrophy. BCVA was 20/125

intravitreal TA, but they affirmed that PCH was not an adverse event and their results of visual acuity were similar to prior studies with combined PDT and intravitreal TA. Severe RPE alterations in the treated area following one single PDT in young people have been reported<sup>[13,14]</sup>. Postelmans *et al*<sup>[13]</sup> described four young female cases

treated by standard PDT for classic CNV with RPE atrophy in the area of treatment spot used in the macula. Two patients gained and two patients lost visual acuity. Wachtlin *et al*<sup>[14]</sup> reported a case of a young female who was treated by one single PDT session improving visual acuity while developing a concentric RPE atrophy corresponding to the PDT treated area. Retinal atrophy after accidental intravitreal injection of steroids was described in 1998<sup>[15]</sup>. RPE atrophy and choriocapillaris hypofluorescence has been reported in association with PDT combined with TA injection<sup>[16]</sup>. Sutter *et al*<sup>[16]</sup> reported four cases in 10 patients (40%) treated with combined therapy for retinal angiomatous proliferation, concluding that combined treatment might create more atrophy leading to vision loss in some cases.

We have found a high incidence of RPE atrophy and choriocapillaris hypofluorescence after combined therapy (45% of the cases) *vs* seven cases (23%) of the matched control group ( $P=0.04$ , Chi-square test). Changes in RPE and choriocapillaris persisted throughout the follow-up period (two years) in both groups. The high frequency of RPE and choriocapillaris atrophy in our series (45%) and the low frequency of PDT sessions (1.6 sessions per patient over two years *vs* 3.8 for the control group) leads us to think that this side effect has been underestimated and is probably related to the effect of steroids. In our series, a low final BCVA may be attributed to RPE atrophy (LogMar 0.87 in cases with RPE atrophy *vs* 0.66 in cases with no RPE atrophy), though the difference was not statistically significant ( $P=0.11$ ).

PDT is known to induce an increased expression of anti-vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF)<sup>[17]</sup>, which may help to reduce ischemic retinal damage secondary to PDT and to recover the affected choriocapillaris. It is not unlikely that steroids may block the upregulation of VEGF induced by PDT<sup>[17]</sup> and subsequently reduce the regenerative capability of the choriocapillaris, inducing focal ischemia and choriocapillaris and RPE atrophy. This mechanism might probably aid increasing the chances of achieving CNV closure. This suspicion is reinforced by the fact that atrophy appeared in the areas treated by PDT, suggesting a mixed mechanism involving PDT and TA.

PDT has been associated with intravitreal injection of ranibizumab to treat CNV both in animal models and in clinical practice<sup>[18,19]</sup>. However, clinical and histological studies have not shown differences in RPE atrophy or reduction in choriocapillaris density compared with eyes treated by PDT alone. This fact may be attributed to the shorter persistence of ranibizumab as compared with TA.

To summarize, our experience shows that 20 mg intravitreal TA injection and PDT is associated with the appearance of RPE and choriocapillaris atrophy in 45% of the cases. These

changes were probably linked to the combined action of PDT and TA.

#### REFERENCES

- 1 Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. *Am J Ophthalmol* 2001;132(3):425-427
- 2 Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L, Sborgia C. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. *Eur J Ophthalmol* 2005;15(1):89-95
- 3 Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. *Br J Ophthalmol* 2003;87:361
- 4 Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. *Arch Ophthalmol* 2003;121(5):667-673
- 5 Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. *Ophthalmology* 2006;113(1):14-22
- 6 Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. *Prog Retin Eye Res* 2005;24(5):587-611
- 7 Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. *Retina* 2007;27(4):458-461
- 8 Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. *Ophthalmology* 2005;112(2):301-304
- 9 Luttrull JK, Spink CJ. Prolongation of choroidal hypofluorescence following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetonide injection. *Retina* 2007;27(6):688-692
- 10 Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. *Retina* 2007;27(4):458-461
- 11 Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. *Br J Ophthalmol* 2002;86(5):527-529
- 12 Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. *Retina* 2000;20(3):244-250
- 13 Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. *Am J Ophthalmol* 2004;138(5):803-808
- 14 Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. *Graefes Arch Clin Exp Ophthalmol* 2003;241(6):518-521
- 15 Modarres M, Parvaresh MM, Peyman GA. Accidental subretinal injection of triamcinolone acetonide. *Ophthalmic Surg Lasers* 1998;29(11):935-938
- 16 Suter FK, Kurz-Levin MM, Fleischhauer J, Bösch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). *Klin Monatsbl Augenheilkd* 2006;223(5):376-378
- 17 Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. *Invest Ophthalmol Vis Sci* 2003;44(10):4473-4480
- 18 Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. *Invest Ophthalmol Vis Sci* 2006;47(1):357-363
- 19 Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. *Arch Ophthalmol* 2006;124(11):1532-1542